VivoSeq
Other

Tremelimumab

0

Pipeline Programs↗

7

Active Trials↗

1

Companies Involved↗

Tremelimumab is an early-stage landscape with 0 programs across 1 company. The most active players are AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed10 · 59%
Recruiting6 · 35%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Recruiting·—·Phase 2·NCT07307456·31 enrolled
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Recruiting·—·Phase 2·NCT06364007·20 enrolled
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06045975·30 enrolled
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Recruiting·—·Phase 1·NCT05701488·20 enrolled
Durvalumab and Tremelimumab in Resectable HCC
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05440864·28 enrolled
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
Recruiting·UUniversity of California, San Diego·Phase 1·NCT06710223·20 enrolled
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04817826·31 enrolled
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Completed·—·Phase 1·NCT03085849·2 enrolled
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT03089645·39 enrolled
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT02040064·27 enrolled
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Completed·LLudwig Institute for Cancer Research·Phase 1·NCT01975831·104 enrolled
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02643303·58 enrolled
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Completed·SSeoul National University Hospital·Phase 2·NCT06446570·18 enrolled
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00378482·37 enrolled
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
Completed·AAIO-Studien-gGmbH·Phase 2·NCT03473574·128 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)